Anika Alvanzo, M.D., M.S., is an Assistant Professor of Medicine at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include addiction medicine and internal medicine. Dr. Alvanzo serves as the Medical Director of the Substance Use Disorders Consultation Service. She is also the Regional Director and Board Member, American Society of Addiction Medicine. Dr. Alvanzo received her M.D. from The George Washington University School of Medicine. She completed her residency and a fellowship in internal medicine at the Virginia Commonwealth University Health System. Her research interests include screening and brief interventions for at-risk substance use and race/ethnicity and sex differences in substance use disorders.
Leo Beletsky, J.D., holds a joint appointment at Northeastern University with the School of Law and Bouvé College of Health Sciences. His expertise is on the use of law to improve health, with focus on drug policy, reducing the spread of infectious disease, and the role of the criminal justice system in shaping public health outcomes. By melding legal and scientific methods, he designs and evaluates interventions such as laws intended to curb opioid overdose and police trainings to align enforcement practices with public health goals. Throughout his career, Professor Beletsky has applied his skills and expertise in service to governmental agencies and nongovernmental organizations, including the United Nations, Department of Justice, and the City of New York.
Prior to joining the Northeastern community, Professor Beletsky was
on the faculty of the Division of Global Public Health at the University of California, San Diego, School of Medicine, where he retains an adjunct appointment. He received his undergraduate training in geography from Vassar College and Oxford University, a master’s in public health from Brown University, his law degree from Temple University School of Law, and his postdoctoral training at the Yale University Center for Interdisciplinary Research on AIDS. He is a member of the New York State Bar.
Katie Burk, M.P.H., is the Viral Hepatitis Coordinator at the San Francisco Department of Public Health (SFDPH). She has extensive experience in nonprofit and government program development, management, evaluation, and capacity building with a focus on promoting the health and well-being of drug users and other marginalized populations. Ms. Burk is a co-founder and Coordinating Committee member of End Hep C SF, San Francisco’s citywide, collective impact hepatitis C virus (HCV) elimination initiative, where she fulfills a leadership role. At SFDPH, she designed and implemented San Francisco’s first HCV linkage programs for vulnerable San Franciscans living with HCV who need support connecting to medical care for HCV treatment. She also partnered with local community-based organization Glide in completing formative research and design of the “New Treatments Have Changed the Game” media campaign around HCV treatment. Ms. Burk also supported the planning, design, and execution of the primary care HCV treatment initiative. Ms. Burk also manages the nationally recognized Drug Overdose Prevention Education (DOPE) program funding contract, as well as contracts for integrated HCV and HIV testing in behavioral health settings.
Prior to her employment at SFDPH, Ms. Burk worked as a Capacity-Building Program Manager at the Harm Reduction Coalition, where she worked nationally to expand syringe access service provision and overdose prevention services. As part of the Health Care for the Homeless team of Public Health Seattle & King County, Ms. Burk evaluated a harm reduction-oriented homeless case management program.
Jonathan Colasanti, M.D., M.S.P.H., joined the Emory University faculty in 2015 as an Assistant Professor with a dual appointment in the School of Medicine (Department of Medicine, Division of Infectious Diseases) and the Rollins School of Public Health (Department of Global Health). He also serves as the Associate Medical Director of the Ponce de Leon Center, Infectious Diseases Program of the Grady Health System. His clinical and research interests focus on the delivery of human immunodeficiency virus (HIV) care to vulnerable populations across the spectrum of the HIV care continuum. In his research, Dr. Colasanti seeks to bridge the implementation gap in order to improve the delivery of HIV care by addressing
sociobehavioral, biomedical, and systems-level barriers. In addition to his Atlanta-based work, he works with a Nicaraguan nongovernmental organization that strives to improve the delivery of primary health care in Nicaragua through a community health worker model.
Dr. Colasanti received his medical degree from the University of Miami Miller School of Medicine in 2008. Subsequently, he completed his internal medicine internship, internal medicine/social medicine and global health equity residency, and public health degree at the University of Miami. He completed his infectious diseases fellowship at Emory University.
Carlos del Rio, M.D., is the Hubert Professor and Chair of the Department of Global Health, a Professor of Epidemiology at the Rollins School of Public Health, and a Professor of Medicine in the Division of Infectious Diseases at the School of Medicine, Emory University. He is also Principal Investigator and Co-Director of the Emory Center for AIDS Research. Dr. del Rio is a native of Mexico, where he attended medical school at Universidad La Salle, graduating in 1983. He did his internal medicine and infectious diseases residencies at Emory University. In 1989 he returned to Mexico, where he was Executive Director of the National AIDS Council of Mexico (CONASIDA, the federal agency of the Mexican Government responsible for AIDS policy throughout Mexico), from 1992 through 1996. In November 1996 he returned to Emory, where he has been involved in teaching and research. Dr. del Rio was Chief of the Emory Medical Service at Grady Memorial Hospital from 2001 to 2009. Dr. del Rio’s research focuses on the early diagnosis, access to care, engagement in care, compliance with antiretrovirals, and prevention of HIV infection. He has worked for over a decade with hard-to-reach populations, including substance abuse users, to improve outcomes of those infected with HIV and to prevent infection with those at risk. He is also interested in the translation of research findings into practice and policy. Dr. del Rio is conducting a National Institute on Drug Abuse–funded study titled “Improving physician opioid prescribing for HIV-infected patients with chronic pain.” He is co-principal investigator (PI) of the National Institutes of Health–funded Emory–Centers for Disease Control and Prevention (CDC) HIV Clinical Trials Unit, Clinical Site Leader for the Adult AIDS Clinical Trials Group, and the site PI for the HIV Prevention Trials Network of the National Institute of Allergy and Infectious Diseases. His international work includes collaborations in the countries of Ethiopia, Georgia, Kenya, Mexico, Thailand, and Vietnam. He has also worked on emerging infections, such as pandemic influenza, and was a member of the World Health Organization Influenza A (H1N1) Clinical Advisory Group and the CDC Influenza A (H1N1) Task Force during the 2009 pandemic.
Dr. del Rio is a Member of the Board of Directors of the International Antiviral Society-USA and former member of the HIV Medicine Association Board and of the Infectious Diseases Society of America Board. He is also a past member of the Advisory Committee on HIV, Hepatitis, and STD Prevention and Treatment of CDC and the Health Resources and Services Administration.
John Dreyzehner, M.D., M.P.H., FACOEM, joined Governor Bill Haslam’s cabinet on September 19, 2011, as the 13th Commissioner of the Tennessee Department of Health. He is a physician with more than 25 years of service in clinical and public health leadership at the federal, state, and local levels. Dr. Dreyzehner began his medical service in 1989 as a U.S. Air Force (USAF) flight surgeon, where he learned about the critical force multiplier effect of the public health mission and the Baldrige performance excellence framework, and accumulated more than 300 hours in the F-15 Eagle and other aircraft as a member of USAF 94th Fighter Squadron and later, Chief of Aeromedical Assessment for Air Combat Command. He was honorably discharged as a major in 1997. Following several years in the private practice of occupational medicine, he returned to public service in 2002 as the director of a multicounty health district in the tri-cities region of central Appalachia before coming to Tennessee as Commissioner. He also practiced in the field of addiction medicine for several years while working to bring attention to the public health aspects of the now well-recognized epidemic.
Ellen Eaton, M.D., is an Assistant Professor in the University of Alabama at Birmingham (UAB) School of Medicine Division of Infectious Diseases, a 2017–2019 Fellow of the National Academy of Medicine, and a UAB Patient-Centered Outcomes Research Institute Mentored Career Development Program Scholar with an interest in human immunodeficiency virus (HIV)/sexually transmitted infection (STI) health outcomes and policy. Her current research evaluates patient preferences related to HIV treatment options and the use of decision analyses to compare the effectiveness of HIV treatments and STI testing strategies. Dr. Eaton recently conducted a study looking at the budgetary impact of compliance with STI screening guidelines in persons living with HIV. This work was presented as an oral presentation at the 2016 annual IDWeek in New Orleans, and was recently published in the Journal of Acquired Immune Deficiency Syndrome. Dr. Eaton is currently preparing a K23 submission to the National Institutes of Health.
Honora Englander, M.D., is an Associate Professor of Medicine at the Oregon Health & Science University (OHSU) School of Medicine. She is
the Principal Investigator of a study aimed at understanding substance use needs among hospitalized adults at OHSU and is the Director of the Improving Addiction Care Team (IMPACT). IMPACT includes an interprofessional inpatient addiction consult service with linkages to community addiction care for medically complex patients with substance use disorders. IMPACT began in July 2015 and has funding support through OHSU and CareOregon.
Oluwaseun Falade-Nwulia, M.B.B.S., M.P.H., is an Assistant Professor of Medicine at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include infectious disease. Dr. Falade-Nwulia earned her M.B.B.S. from the University of Ibadan Medical School College of Medicine. She completed her residency at the Johns Hopkins Bayview Medical Center. She performed fellowships in infectious diseases at Johns Hopkins and a fellowship in critical care medicine at the National Institutes of Health.
Admiral Brett Giroir, M.D., was sworn in as Assistant Secretary for Health at the Department of Health and Human Services (HHS) on February 15, 2018. The Assistant Secretary for Health leads development of HHS-wide public health policy recommendations, oversees 11 core public health offices—including the Office of the Surgeon General and the U.S. Public Health Service Commissioned Corps, which has approximately 6,500 uniformed health officers who serve in nearly 600 locations around the world to promote, protect, and advance the health and safety of the nation and the world. He also oversees 3 presidential and 11 secretarial advisory committees.
Dr. Giroir is a physician, scientist, and innovator. He is a former medical school executive and biotech startup Chief Executive Officer (CEO), and has served in a number of leadership positions in the federal government as well as academia.
From 2014–2015, Dr. Giroir chaired the Veterans Choice Act Blue Ribbon Panel to reform the U.S. Veterans Health System. During the Ebola emergency, he directed the Texas Task Force on Infectious and Disease Preparedness Response.
He was Executive Vice President and CEO of Texas A&M’s Health Science Center from 2013 to 2015, having earlier served as Vice Chancellor of strategic initiatives (2011–2013) and Vice Chancellor for research (2008–2011) for the entire Texas A&M University system. A pediatric critical care physician and a former member of the American Board of Pediatrics, Dr. Giroir cared for critically ill children for 14 years, and was the first Chief Medical Officer of Children’s Medical Center of Dallas (now Children’s Health). He was also a Professor at the University of Texas
Southwestern Medical Center from 1993 to 2003, and held a number of positions in academic and hospital leadership.
Dr. Giroir has had a significant federal portfolio. He directed the Defense Sciences Office of the Defense Advanced Research Projects Agency (DARPA) from 2006 to 2008. In this capacity, he worked regularly with the White House, Congress, and the National Institutes of Health, the Centers for Disease Control and Prevention, the Department of Homeland Security, and the Central Intelligence Agency leadership on national priorities, strategies, and programs. He joined the office in 2004 as Deputy Director, and between 1998 and 2004, was a member of the Defense Sciences Research Council.
Dr. Giroir has authored or co-authored almost 100 peer-reviewed scientific publications and holds patents on a number of biomedical inventions. He is the recipient of numerous honors and awards, including the U.S. Secretary of Defense Medal for Outstanding Public Service, the American Heart Association’s President Lyndon Baines Johnson Research Award, and the Society of Critical Care Medicine’s Annual Scientific Award. He was the nation’s high school debate champion in 1978. He received a bachelor’s degree in biology from Harvard University in 1982 and a medical degree from the University of Texas Southwestern Medical Center (Dallas) in 1986.
Captain Katie Goodwin, M.S., was hired by the Anne Arundel County Police Department in 1994, where she worked patrol and then as a detective in the Criminal Investigation Division, Sex Offense Unit. While assigned in this unit, she received the Department Commendation Award for the successful apprehension of a serial rapist. In 2000, she was promoted to Sergeant and assigned to the Intelligence Section, where she oversaw the Executive Protection Unit and provided security for the Anne Arundel County Executive. In 2002, she returned to the Criminal Investigation Division, where she was the commander of the Sex Offense Unit. In July 2005, she was promoted to Lieutenant and has served as a patrol commander and Executive Officer for two districts. In 2012, she took command of the Homeland Security and Intelligence Section and was responsible for implementing the first Gang Unit for the Agency. She was promoted to Captain in June 2015, where she remained as the commander for Western District until September 2017. In September 2017, she took command of the Criminal Investigation Division, which oversees three sections: the Major Crimes Section (Homicide, Sex Offense, Child & Vulnerable Adult Abuse Cases); Organized & Economic Crimes Section (Commercial Robberies, Economic Crimes, Homeland Security & Intelligence); and Narcotics & Special Investigations Section (Major Offenders, Heroin Task Force, Vice/Prescription Fraud, Metal Thefts,
and the Fugitive Apprehension Team), as well as the Forensic Services. Two distinguished awards Captain Goodwin is most proud of receiving are the Department’s Silver Star Award for her leadership as the Civil Disturbance Unit’s Commander during the Baltimore City Riots of April 2015 and the Anne Arundel County Chamber of Commerce’s award of “Women Who Make a Difference” in 2017.
Captain Goodwin received a Bachelor of Arts Degree in Criminal Justice from the University of Maryland, College Park, and her Master of Science Degree in Business Management from Johns Hopkins University.
Traci G. Green, Ph.D., M.Sc., is the Deputy Director of the Boston Medical Center Injury Prevention Center and an Associate Professor of Emergency Medicine and Epidemiology at the Warren Alpert School of Medicine at Brown University. She is an epidemiologist whose research focuses on drug abuse, addiction, and injury. She earned a master’s in epidemiology and biostatistics from McGill University and a Ph.D. in epidemiology from Yale University. She helped design the ASI-MV, a real-time illicit and prescription drug abuse surveillance system developed by Inflexxion, Inc. Dr. Green helped cofound prescribetoprevent.org, chairs the Drug Overdose Prevention and Rescue Coalition for the Rhode Island Department of Health, and serves as an advisor to the governor on addiction and overdose. Dr. Green serves on the Board of Scientific Counselors for the Centers for Disease Control and Prevention’s (CDC’s) National Center for Injury Prevention and Control. Her research is supported by CDC, the National Institute on Drug Abuse, the Department of Justice, the Agency for Healthcare Research and Quality, and the Patient-Centered Outcomes Research Institute.
Nicole Greene serves as Deputy Director for the Department of Health and Human Services’ Office on Women’s Health (OWH) and acts as the primary advisor to the Deputy Assistant Secretary for Health—Women’s Health. A former Council for Excellence in Government Fellow and a graduate of the prestigious Leadership for a Democratic Society program through the Federal Executive Institute, Ms. Greene leads change management in the office. One of her first projects at OWH was to lead the restructuring of OWH, improving the efficiency and effectiveness by aligning the mission of the office so it can better serve American women and girls.
Ms. Greene oversees all administrative, financial, and strategic planning, as well as program and management operations, including the office’s annual budget and related congressional justifications. She also guides all aspects of personnel management, staff development, and staff performance-related activities. Ms. Greene serves as a spokesperson
for OWH, speaking on such topics as domestic violence and National Women’s Health Week.
Before joining OWH, Ms. Greene spent more than 20 years at the Health Resources and Services Administration (HRSA), where she most recently served as Senior Administrative Officer and Operations and Administration Team Lead for HRSA’s Bureau of Health Professions (BHPr). During her time at HRSA, she also led the Policy and Analysis Branch of BHPr’s National Practitioner Data Bank. Ms. Greene also spent many years in various roles within HRSA’s Bureau of Primary Health Care, including more than 7 years as a Senior Project Officer for the Community Health Center program. Her dynamic and extensive experience in public health has contributed to her overall proficiency in federal program management and oversight, operations, and administrative management, making her a valuable resource to OWH and the Office of the Assistant Secretary for Health.
Elisabeth Houtsmuller, Ph.D., is an Associate Director in the Healthcare Delivery and Disparities Research program at the Patient-Centered Outcomes Research Institute (PCORI). Before PCORI, Dr. Houtsmuller led the Green Park Collaborative at the Center for Medical Policy Technology, where she also served as vice president of research. Prior to her work there, she was managing editor of health technology assessments (HTAs) at Hayes, Inc., leading a team of writers and the production of numerous HTAs on a wide range of medical and mental health topics. In addition, she led the Behavioral and Mental Health Services program at Hayes, Inc. Earlier, she was an Associate Professor in the Department of Psychiatry at the Johns Hopkins University School of Medicine, where she served as principal investigator on several research grants and directed a human subjects research laboratory focused on drug abuse and addiction. Her work has been published in numerous peer-reviewed papers, book chapters, and health technology assessments. Dr. Houtsmuller serves as the Chair of an institutional review board for a small research group in Baltimore. Dr. Houtsmuller received a Ph.D. in physiological psychology from Erasmus University in the Netherlands and completed postdoctoral work at the Johns Hopkins University School of Medicine.
Van Ingram is the Executive Director for the Kentucky Office of Drug Control Policy (ODCP). Mr. Ingram joined ODCP in November 2004, shortly after it was created, with the mission of coordinating Kentucky’s substance abuse efforts in enforcement, treatment, and prevention/education.
Mr. Ingram served with the Maysville, Kentucky, Police Department for more than 23 years, the last 6 as Chief of Police. He is a former Presi-
dent of the Kentucky Association of Chiefs of Police, and was named “Kentucky Chief of the Year” in 2001. He is the 2004 recipient of the Governor’s Award for Outstanding Contribution to Law Enforcement, as well as the Melvin Shein Award for distinguished service to Kentucky law enforcement. Mr. Ingram is a certified law enforcement instructor and has trained officers across the state on a variety of topics, including community-oriented policing, case management, and “Kentucky Substance Abuse Issues” for chiefs, sheriffs, and command staff. He is a frequent speaker on a variety of substance abuse issues both in Kentucky and nationally.
P. Todd Korthuis, M.D., serves as Program Director for the Oregon Health & Science University’s (OHSU’s) Addiction Medicine Fellowship and Co-Director of the Oregon Addiction Education and Prevention Initiative that provides training and support for rural primary care providers in pharmacotherapy for substance use disorders. He is also a practicing general internist, addiction medicine provider, and clinician scientist. He began his clinical career treating patients living with HIV and became board-certified in addiction medicine in 2010. His research focuses on improving integration of addiction treatment in diverse health care settings, including HIV clinics. He serves as principal investigator for two international trials funded by the National Institute on Drug Abuse (NIDA): the CTN-0055/0067 CHOICES trial of clinic-based extended-release naltrexone in North American HIV clinics, and the BRAVO trial of clinic-based buprenorphine for opioid use disorder in Vietnamese HIV clinics. He is co-investigator in the NIDA Clinical Trials Network Western States Node, collaborating in clinical trials of opioid, methamphetamine, and cocaine treatment. His honors include the 2008 Lawrence S. Linn Award for research that improves the lives of people living with HIV and a 2012–2013 Fulbright Scholar award to study integration of HIV and addiction care in Vietnam.
Matthew La Rocco, CADC, is the Community Liaison for the Louisville Metro Syringe Exchange Program. Through his work at the Louisville Metro Syringe Exchange Program, he has learned how choosing to “meet people where they are at” increases his ability as a practitioner to help others build motivation for change, elicit change behavior, and experience positive outcomes. Mr. La Rocco is frequently asked to speak about harm reduction, building community, and organizational capacity to effectively engage relationally with people who use drugs, and improving outcomes for patients and staff.
Benjamin Linas, M.D., M.P.H., is an Associate Professor of Medicine at Boston University School of Medicine. He is a national leader in hepatitis C virus (HCV) infection and HCV/HIV co-infection comparative- and cost-effectiveness research using computational biology, clinical epidemiology, and clinical economics methods. Dr. Linas has an excellent track record of productivity, ample funding from the National Institutes of Health and the Centers for Disease Control and Prevention, and a growing core of successful trainees. Dr. Linas directs the HIV/HCV core of the Center for Health Economics of Treatment Interventions for Substance Use Disorders, HCV, and HIV, funded by the National Institute on Drug Abuse in collaboration with Cornell University, University of Pennsylvania, and Miami University.
Natasha Martin, D.Phil., is an Associate Professor in the Division of Global Public Health in the Department of Medicine at the University of California, San Diego. She is also an Honorary Senior Lecturer at the University of Bristol. Dr. Martin is an infectious disease and economic modeler with more than 15 years of experience modeling biological systems. She earned her doctoral degree in mathematical biology from the University of Oxford and her undergraduate degree in mathematics and biology from Stanford University. Following her doctorate, she worked as a postdoctoral fellow at the University of Bristol and London School of Hygiene & Tropical Medicine.
Dr. Martin’s work focuses on using dynamic epidemic modeling to evaluate the impact and cost-effectiveness of HIV, HCV, and hepatitis B prevention interventions among high-risk populations such as people who inject drugs, men who have sex with men, and incarcerated populations. She is one of the leading researchers examining the potential impact and cost-effectiveness of HCV treatment as prevention. Currently she is engaged in a number of HIV and HCV intervention evaluation trials in international settings such as Australia, India, Kenya, Mexico, Mozambique, Ukraine, and the United Kingdom.
Veda Moore is a resident of Baltimore, Maryland. She works as a Johns Hopkins HealthCare Community Care Coordinator.
William Powderly, M.D., is the Dr. J. William Campbell Professor of Medicine and the Larry J. Shapiro Director of the Institute for Public Health at Washington University in St. Louis. He is also Co-Director of the Division of Infectious Diseases at the Washington University School of Medicine. From 2005 to 2012, he was the Dean of Medicine and Head of the School of Medicine.
Dr. Powderly has been actively involved in HIV-related clinical research for almost 30 years. He has been a member of numerous advisory groups on HIV and infectious diseases for the National Institutes of Health, the Centers for Disease Control and Prevention, the Canadian Institute for Health Research, and the European Medicines Agency. As Director of the Institute for Public Health, Dr. Powderly is particularly interested in finding ways to translate the significant advances in biomedical science into improvements in population and community health. He is a Fellow of the Royal College of Physicians in Ireland and of the American Association for the Advancement of Science, and is, currently, President of the Infectious Diseases Society of America.
Josiah “Jody” D. Rich, M.D., M.P.H., is a Professor of Medicine and Epidemiology at the Warren Alpert Medical School of Brown University. He is also a practicing infectious disease specialist since 1994 at the Miriam Hospital Immunology Center, providing clinical care for more than 22 years, and at the Rhode Island Department of Corrections, caring for prisoners with HIV infection and working in the correctional setting doing research. He has published close to 190 peer-reviewed publications, predominantly in the overlap between infectious diseases, addictions, and incarceration. He is the Director and Co-Founder of the Center for Prisoner Health and Human Rights at the Miriam Hospital (www.prisonerhealth.org). He is also a Co-Founder of the nationwide Centers for AIDS Research Collaboration in HIV in Corrections Initiative. Dr. Rich has advocated for public health policy changes to improve the health of people with addiction, including improving legal access to sterile syringes and increasing drug treatment for the incarcerated and formerly incarcerated populations. He is the Principal Investigator of three R01 grants and one K24 grant, all focused on incarcerated populations. His primary field and area of specialization and expertise is in the overlap between infectious diseases and illicit substance use, the treatment and prevention of HIV infection, and the care and prevention of disease in addicted and incarcerated individuals.
He has served as an expert for the National Academy of Sciences, the Institute of Medicine, and many others. He has been appointed by Rhode Island Governor Gina Raimondo to the Overdose Prevention and Intervention Task Force Expert Team, selected to advise the task force and formulate a strategic plan to address addiction and stop overdose in Rhode Island. The Rhode Island Overdose Prevention and Intervention Task Force was created to propose a strategic plan that puts forth the most effective initiatives in the areas of prevention of opioid addiction, reversal of opioid overdose, treatment of opioid addiction, and recovery to reduce
addiction and stop overdose death in Rhode Island. Its efforts are targeted at identifying the components for prevention, treatment, reversal, and recovery that will shift the epidemic curve of overdose deaths.
Sandra Springer, M.D., is an Associate Professor of Medicine in the Department of Internal Medicine, Section of Infectious Diseases, at the Yale School of Medicine. She is also the Director of the Infectious Disease (ID) Clinic at the Newington site and an attending ID physician at the West Haven site of the Veterans Affairs Connecticut Healthcare System. She is board-certified in internal medicine, infectious diseases, and addiction medicine. She has significant clinical and research experience with persons with alcohol and substance use disorders (SUDs) and with persons living with HIV (PLH). She has completed a 5-year National Institute on Drug Abuse (NIDA) K02 Independent Scientist Award developing interventions to improve adherence to antiretroviral therapy among PLH with comorbid SUDs. She was also a former recipient of an NIDA-funded K23 Mentored Career Development Award where she evaluated the use of medication-assisted treatment (MAT) to prevent relapse to opioid use as a conduit to care among HIV-infected, opioid-dependent released prisoners. During this project she developed the first protocol to use buprenorphine to improve HIV treatment outcomes as relapse prevention for opioid dependent HIV-positive prisoners.
She has considerable research experience conducting randomized controlled trials with the use of extended-release naltrexone (XR-NTX) and has been a Principal Investigator (PI) on several R01s, including one funded by the National Institute on Alcohol Abuse and Alcoholism to evaluate XR-NTX to improve HIV treatment outcomes via preventing relapse to alcohol use among HIV-infected prisoners with alcohol use disorders transitioning to the community and an NIDA R01 that evaluated XR-NTX to improve HIV treatment outcomes and prevent relapse to opioid use among opioid-dependent released criminal justice–populations. She was recently awarded an R01 from NIDA as co-PI evaluating immunobiological outcomes among persons with opioid use disorders starting MAT. In addition, she has been co-investigator on two R01s funded by NIDA: (1) using buprenorphine to improve HIV and opioid treatment outcomes among HIV positive persons with a history of criminal justice system involvement in Washington, DC; and (2) to implement MAT with XR-NTX with opioid-dependent persons in Ukraine. Thus, she has considerable expertise with HIV and SUDs and conducting research.
Patrick Sullivan, Ph.D., D.V.M., is a Professor of Epidemiology in the Rollins School of Public Health, Emory University. He has worked on
HIV testing programs with migrant farm workers, with the inclusion of Hispanic participants in online sexual health surveys. Dr. Sullivan has also investigated methods to increase participation of African American and Latino men who have sex with men (MSM) in his research. Dr. Sullivan has worked with MSM prevention and vaccine studies in Brazil and Peru. Dr. Sullivan’s most current research in the United States focuses on a MSM testing initiative targeting African American and Latino MSM. The MSM testing initiative will have a Spanish language sexual health survey to better target Latino men. Dr. Sullivan acknowledges the large program of research with African American MSM in Atlanta and plans to develop parallel research capacity with Latino MSM in Atlanta.
Dace Svikis, Ph.D., is a Professor in the Departments of Psychology, Psychiatry, and Obstetrics/Gynecology at Virginia Commonwealth University (VCU). She is also Deputy Director of the VCU Institute for Women’s Health and Director of the Addiction and Women’s Health (AWHARE) Program. Dr. Svikis has been involved in addiction research for nearly 30 years and is best known for her work in perinatal addiction. While at Johns Hopkins University, Dr. Svikis directed the Center for Addiction and Pregnancy, a model multidisciplinary treatment program for pregnant women with opioid and other substance use disorders (SUDs). In recognition of her success integrating research with clinical practice, Dr. Svikis received the Dan Anderson award for Advancement of Scientific Knowledge in Addiction Treatment from Hazelden. During that time, Dr. Svikis also spearheaded acquirement of Ryan White funding to provide primary care and mental health services on the Hopkins Bayview campus to the drug-dependent pregnant and postpartum women who were also living with HIV.
She has served as the Principal Investigator (PI) or Co-PI on numerous National Institutes of Health grants, including several randomized controlled trials of behavioral, psychosocial, and pharmacological treatments for opioid and other SUDs. She is a member of the Mid-Atlantic Node of the National Institute on Drug Abuse Clinical Trials Network, and for the past 15–20 years has been involved in translational research and the dissemination of evidence-based practices (e.g., motivational interviewing, safer sex skill building) to a broad range of medical and mental health care providers. As Deputy Director of the VCU Institute for Women’s Health, Dr. Svikis is particularly committed to the mentoring of students and faculty in the conduct of research, emphasizing the importance of considering sex/gender as a variable from the point of study design through the analyses of data and publication of research findings.
Richard Wolitski, Ph.D., is the Director of the Office of HIV/AIDS and Infectious Disease Policy at the Department of Health and Human Services. This office is responsible for developing, coordinating, and supporting the implementation of policies, programs, and activities related to HIV, viral hepatitis, and other infectious diseases of public health significance, as well as the safety and availability of blood and tissue products. Dr. Wolitski has worked for three decades as a researcher studying HIV, viral hepatitis, and sexually transmitted disease risks and prevention among gay and bisexual men, people who inject drugs, and other populations. He is the author of more than 130 scientific articles, chapters, and reports and he has co-edited three books. He earned his Ph.D. in community psychology from Georgia State University and his master’s degree in psychology from California State University, Long Beach.
Nickolas Zaller, Ph.D., is an Associate Professor in the College of Public Health Department of Health Behavior and Health Education and is Director of the University of Arkansas for Medical Sciences Office of Global Health. Dr. Zaller’s approach to public health research is global in scope and multidisciplinary, at times including medicine, pharmacy, the social and behavioral sciences, nursing, and law. Mentoring students, postdoctoral fellows, and medical residents has also been a strong theme throughout his academic career.
Dr. Zaller’s interest in international public health dates back to his undergraduate education and now extends to four other continents. While a student at Kansas University, he earned a bachelor’s degree in microbiology and East Asian studies. Following graduation, he was a Fulbright Scholar in Beijing, China. He went on to earn a Ph.D. in international health and infectious disease epidemiology from the Johns Hopkins Bloomberg School of Public Health. He returned to China to spend 2 years doing doctoral research on blood donation practices, HIV risk, and cultural beliefs about blood.
While Dr. Zaller was faculty for 7 years at Brown University’s Alpert Medical School, his research, teaching, and mentorship activities focused on the interconnection of infectious disease, illicit substance use, and incarceration. He continues to be involved in an interdisciplinary research team composed of colleagues at Brown University and Anhui Medical University and School of Public Health in Anhui, China. The team has examined the health outcomes of rural-to-urban migration, particularly HIV risk among women, and currently is investigating factors that affect HIV testing among men in China who have sex with men and women.
Dr. Zaller has also developed ongoing collaborations with Ukrainian researchers on policy strategies for treating HIV and tuberculosis among injection drug users. He has also served as a consultant to colleagues in Chile, India, and Kenya.